Comparative Pharmacology
Head-to-head clinical analysis: PHENAZINE versus PHENAZINE 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENAZINE versus PHENAZINE 35.
PHENAZINE vs PHENAZINE-35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenazine is a phenothiazine neuroleptic that blocks postsynaptic D2 dopamine receptors in the mesolimbic and mesocortical pathways, thereby alleviating positive symptoms of schizophrenia. It also has anticholinergic (M1 receptor blockade), alpha1-adrenergic receptor antagonism, and H1-histamine receptor antagonism properties, contributing to its adverse effect profile.
PHENAZINE-35 is a synthetic phenazine derivative that inhibits bacterial DNA synthesis by intercalating into DNA and disrupting topoisomerase IV activity, leading to cell death.
Phenazine is not a standard pharmaceutical agent. The name is ambiguous and may refer to a chemical compound (phenazine) or a historical preparation. No established dosing exists.
25 mg orally three times daily, titrated to a maximum of 100 mg three times daily.
None Documented
None Documented
Clinical Note
moderateFluphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone propionate."
Clinical Note
moderatePerphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone propionate."
Clinical Note
moderateFluphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Fluphenazine."
Clinical Note
moderateTerminal half-life approximately 6-10 hours; may be prolonged in hepatic or renal impairment, requiring dose adjustment.
Terminal half-life: 12-18 hours (mean 15 h). Clinically, steady-state achieved in ~3 days, allows once-daily dosing.
Primarily renal (up to 80% as unchanged drug and metabolites), with approximately 15% biliary/fecal elimination.
Renal: ~70% (30% unchanged, 40% as metabolites); Biliary/Fecal: ~30%
Category C
Category C
Urinary Analgesic
Urinary Analgesic
Perphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Perphenazine."